WO2003045942A3 - Chemokine receptor antagonists and methods of use thereof - Google Patents
Chemokine receptor antagonists and methods of use thereof Download PDFInfo
- Publication number
- WO2003045942A3 WO2003045942A3 PCT/US2002/036953 US0236953W WO03045942A3 WO 2003045942 A3 WO2003045942 A3 WO 2003045942A3 US 0236953 W US0236953 W US 0236953W WO 03045942 A3 WO03045942 A3 WO 03045942A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methods
- receptor antagonists
- chemokine receptor
- activation
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
- C07D313/02—Seven-membered rings
- C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
- C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D313/12—[b,e]-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
Abstract
Priority Applications (26)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE60209937A DE60209937D1 (en) | 2001-11-21 | 2002-11-13 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF THEIR APPLICATION |
EA200400692A EA008060B1 (en) | 1998-09-04 | 2002-11-13 | Chemokine receptor antagonists and methods of use thereof |
CA2467672A CA2467672C (en) | 2001-11-21 | 2002-11-13 | Chemokine receptor antagonists and methods of use therefor |
CN02827426.1A CN1585772B (en) | 2001-11-21 | 2002-11-13 | Chemokine receptor antagonists and methods of use thereof |
US10/487,168 US7271176B2 (en) | 1998-09-04 | 2002-11-13 | Chemokine receptor antagonists and methods of use thereof |
AU2002352772A AU2002352772B2 (en) | 2001-11-21 | 2002-11-13 | Chemokine receptor antagonists and methods of use thereof |
IL16166902A IL161669A0 (en) | 2001-11-21 | 2002-11-13 | Chemokine receptor antagonists and methods of use thereof |
DE60209937T DE60209937T4 (en) | 2001-11-21 | 2002-11-13 | Chemokine receptor antagonists and methods of use |
DK02789725T DK1448566T5 (en) | 2001-11-21 | 2002-11-13 | Chemokine Receptor Antagonists and Methods for Using Them |
JP2003547392A JP4889920B2 (en) | 2001-11-21 | 2002-11-13 | Chemokine receptor antagonist and method of use thereof |
SI200230327T SI1448566T1 (en) | 2001-11-21 | 2002-11-13 | Chemokine receptor antagonists and methods of use thereof |
NZ532827A NZ532827A (en) | 2001-11-21 | 2002-11-13 | Chemokine receptor antagonists and methods of use thereof |
MXPA04004826A MXPA04004826A (en) | 1998-09-04 | 2002-11-13 | Chemokine receptor antagonists and methods of use thereof. |
BR0213633-3A BR0213633A (en) | 2001-11-21 | 2002-11-13 | Method and compound for treating a disease associated with aberrant leukocyte recruitment and / or activation |
KR1020047007728A KR100919346B1 (en) | 2001-11-21 | 2002-11-13 | Chemokine receptor antagonists and methods of use thereof |
HU0500079A HU228314B1 (en) | 1998-09-04 | 2002-11-13 | Chemokine receptor antagonists, their use and pharmaceutical compositions containing them |
EP02789725A EP1448566B3 (en) | 2001-11-21 | 2002-11-13 | Chemokine receptor antagonists and methods of use thereof |
IL161669A IL161669A (en) | 2001-11-21 | 2004-04-29 | Chemokine receptor antagonists and methods of use thereof |
NO20042500A NO328166B1 (en) | 2001-11-21 | 2004-06-15 | Chemokine receptor antagonists, pharmaceutical compositions containing them, such compounds for use in therapy and the use of such compounds for the manufacture of medicaments for the treatment of disease |
HK04106595A HK1063789A1 (en) | 2001-11-21 | 2004-09-02 | Chemokine receptor antagonists and methods of use thereof |
US11/595,653 US7541365B2 (en) | 2001-11-21 | 2006-11-10 | Chemokine receptor antagonists and methods of use therefor |
IL181191A IL181191A (en) | 2001-11-21 | 2007-02-06 | Pyrrolidine derivatives, pharmaceutical compositions comprising them and uses thereof for the manufacture of a medicament for treating a disease associated with aberrant leukocyte recruitment, activation or recruitment and activation |
US12/436,271 US8058287B2 (en) | 2001-11-21 | 2009-05-06 | Chemokine receptor antagonists and methods of use therefor |
US13/245,436 US8653096B2 (en) | 2001-11-21 | 2011-09-26 | Chemokine receptor antagonists and methods of use thereof |
US14/105,750 US20140371207A1 (en) | 2001-11-21 | 2013-12-13 | Chemokine receptor antagonists and methods of use thereof |
US14/643,773 US9663537B2 (en) | 2001-11-21 | 2015-03-10 | Chemokine receptor antagonists and methods of use |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/148,823 US6613905B1 (en) | 1998-01-21 | 1998-09-04 | Chemokine receptor antagonists and methods of use therefor |
US09/235,102 US6329385B1 (en) | 1998-01-21 | 1999-01-21 | Chemokine receptor antagonists and methods of use therefor |
US09/362,837 US6509346B2 (en) | 1998-01-21 | 1999-07-28 | Chemokine receptor antagonists and methods of use therefor |
US62788600A | 2000-07-28 | 2000-07-28 | |
US09/989,086 US20020169155A1 (en) | 1998-09-04 | 2001-11-21 | Chemokine receptor anagonists and methods of use therefor |
US09/989,086 | 2001-11-21 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/989,086 Continuation-In-Part US20020169155A1 (en) | 1998-09-04 | 2001-11-21 | Chemokine receptor anagonists and methods of use therefor |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/487,168 A-371-Of-International US7271176B2 (en) | 1998-09-04 | 2002-11-13 | Chemokine receptor antagonists and methods of use thereof |
US10487168 A-371-Of-International | 2002-11-13 | ||
US11/595,653 Continuation US7541365B2 (en) | 2001-11-21 | 2006-11-10 | Chemokine receptor antagonists and methods of use therefor |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003045942A2 WO2003045942A2 (en) | 2003-06-05 |
WO2003045942A3 true WO2003045942A3 (en) | 2003-09-12 |
Family
ID=46204639
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/036953 WO2003045942A2 (en) | 1998-09-04 | 2002-11-13 | Chemokine receptor antagonists and methods of use thereof |
Country Status (4)
Country | Link |
---|---|
EA (1) | EA008060B1 (en) |
HU (1) | HU228314B1 (en) |
MX (1) | MXPA04004826A (en) |
WO (1) | WO2003045942A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9334283B2 (en) | 2002-11-13 | 2016-05-10 | Millennium Pharmaceuticals, Inc. | CCR1 antagonists and methods of use thereof |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7541365B2 (en) | 2001-11-21 | 2009-06-02 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
CN1964979B (en) | 2004-04-09 | 2011-07-27 | 中外制药株式会社 | Novel water-soluble prodrug |
CN101119725B (en) * | 2004-12-17 | 2013-04-17 | 千禧药品公司 | Solid forms of a chemokine receptor antagonist and methods of use thereof |
EP1954133A4 (en) * | 2005-11-30 | 2010-11-24 | Glaxosmithkline Llc | Pyrrolidineanilines |
JP2007297306A (en) * | 2006-04-28 | 2007-11-15 | Kaneka Corp | Method for producing optically active 3-(1-pyrrolidinyl)pyrrolidine |
PT2229356E (en) | 2007-12-03 | 2012-01-20 | Novartis Ag | 1,2-disubstituted-4-benzylamino-pyrrolidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperli pidemia or arteriosclerosis |
WO2009104557A1 (en) * | 2008-02-21 | 2009-08-27 | 株式会社カネカ | Process for production of n-(3-pyrrolidinyl)glycine derivative |
US9145383B2 (en) | 2012-08-10 | 2015-09-29 | Hallstar Innovations Corp. | Compositions, apparatus, systems, and methods for resolving electronic excited states |
US9867800B2 (en) | 2012-08-10 | 2018-01-16 | Hallstar Innovations Corp. | Method of quenching singlet and triplet excited states of pigments, such as porphyrin compounds, particularly protoporphyrin IX, with conjugated fused tricyclic compounds have electron withdrawing groups, to reduce generation of reactive oxygen species, particularly singlet oxygen |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996031469A1 (en) * | 1995-04-07 | 1996-10-10 | Novo Nordisk A/S | N-substituted azaheterocyclic carboxylic acids and esters thereof |
WO1999037651A1 (en) * | 1998-01-21 | 1999-07-29 | Millenium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
WO2001009138A2 (en) * | 1999-07-28 | 2001-02-08 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
-
2002
- 2002-11-13 MX MXPA04004826A patent/MXPA04004826A/en active IP Right Grant
- 2002-11-13 EA EA200400692A patent/EA008060B1/en not_active IP Right Cessation
- 2002-11-13 WO PCT/US2002/036953 patent/WO2003045942A2/en active Application Filing
- 2002-11-13 HU HU0500079A patent/HU228314B1/en not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996031469A1 (en) * | 1995-04-07 | 1996-10-10 | Novo Nordisk A/S | N-substituted azaheterocyclic carboxylic acids and esters thereof |
WO1999037651A1 (en) * | 1998-01-21 | 1999-07-29 | Millenium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
WO2001009138A2 (en) * | 1999-07-28 | 2001-02-08 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9334283B2 (en) | 2002-11-13 | 2016-05-10 | Millennium Pharmaceuticals, Inc. | CCR1 antagonists and methods of use thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2003045942A2 (en) | 2003-06-05 |
EA200400692A1 (en) | 2004-12-30 |
HUP0500079A2 (en) | 2005-04-28 |
EA008060B1 (en) | 2007-02-27 |
HUP0500079A3 (en) | 2009-03-30 |
HU228314B1 (en) | 2013-03-28 |
MXPA04004826A (en) | 2004-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001009138A3 (en) | Chemokine receptor antagonists and methods of use therefor | |
IL137266A0 (en) | Heterocyclic chemokine receptor antagonists and pharmaceutical compositions containing the same | |
CA2326804A1 (en) | Compounds with activity on muscarinic receptors | |
WO1998002151A3 (en) | Chemokine receptor antagonists and methods of use therefor | |
EP1574219A3 (en) | Method of inhibiting fibrosis with a somatostatin agonist | |
CA2105071A1 (en) | Use of nicotinic analogs for treatment of degenerative diseases of the nervous system | |
BG103740A (en) | Phytostyrene composition for the prevention of the alzheimer's disease | |
CA2284732A1 (en) | Analogs of cocaine | |
WO2003048164A3 (en) | Adenosine a2a receptor antagonists | |
WO2002085861A8 (en) | Imidazolidine compounds and their use as cxcr3 antagonists | |
EP0911331A3 (en) | Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use | |
CA2326339A1 (en) | Use of dexmedetomidine for icu sedation | |
WO2003045942A3 (en) | Chemokine receptor antagonists and methods of use thereof | |
CA2179015A1 (en) | Use of bis(amidinobenzimidazoles) in the manufacture of medicament for inhibiting retroviral integrase | |
CA2132544A1 (en) | Angiotensin ii antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy | |
EA200000693A1 (en) | ANTAGONISTS OF THE CHEMOKINE RECEPTOR AND METHODS OF THEIR APPLICATION | |
WO2001009119A3 (en) | Chemokine receptor antagonists | |
EP0342587A3 (en) | Thienotriazolodiazepine compounds and pharmaceutical uses thereof | |
SG165152A1 (en) | Chemokine receptor antagonists and methods of use thereof | |
CA2322229A1 (en) | Compositions comprising heparin and soluble tnf receptors for inhibition of tnf activity | |
AU6053496A (en) | The use of sertraline to treat post myocardial infarction patients | |
WO2001009094A3 (en) | Chemokine receptor antagonists and methods of use therefor | |
NZ504124A (en) | Phenyl-alkyl-imidazoles and use in treating inflammatory disease | |
CA2065889A1 (en) | Increasing the choroidal blood flow | |
EP0353474A3 (en) | Glycerin derivative and its pharmacological use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 1200400594 Country of ref document: VN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 161669 Country of ref document: IL Ref document number: 1154/DELNP/2004 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002352772 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 532827 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004/03530 Country of ref document: ZA Ref document number: 200403530 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2467672 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2004/004826 Country of ref document: MX Ref document number: 1020047007728 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003547392 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1-2004-500734 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200400692 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002789725 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20028274261 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2002789725 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10487168 Country of ref document: US |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002789725 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 181191 Country of ref document: IL |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002352772 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12007501941 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077024914 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020107000732 Country of ref document: KR |